CRIS Curis, Inc.

NASDAQ
$1.80

Curis, Inc. (CRIS) is expected to report earnings on November 13, 2026, after the market close. The consensus earnings estimate is a loss of $5.87 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.6% since its last earnings release on August 14, 2026.

Curis Beat Consensus Estimates
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 4:00 PM ET
Earnings Whisper
-
vs ($5.87)
Rev est $999
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.58

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Curis, Inc.

Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers. Its products include CUDC-907, phosphatidylinositol-3-kinase and small molecule inhibitor of histone deacetylase.

Sector

Healthcare

Industry

Biotechnology